Immunotherapy is rapidly gaining its place as a standard treatment for solid tumors 1,2 , including lung cancer 3 . Nonetheless, only ~30% of patients benefit from this approach 4 . Much remains to be learned about how immunotherapy works and how to choose the right treatment or combination of treatments for a particular patient. Understanding the mechanisms and molecular basis of effective anti-tumor immune responses will be essential for the development of novel immunotherapeutic agents for those patients who do not respond to the immunotherapies now available.
Immunotherapy is rapidly gaining its place as a standard treatment for solid tumors 1,2 , including lung cancer 3 . Nonetheless, only ~30% of patients benefit from this approach 4 . Much remains to be learned about how immunotherapy works and how to choose the right treatment or combination of treatments for a particular patient. Understanding the mechanisms and molecular basis of effective anti-tumor immune responses will be essential for the development of novel immunotherapeutic agents for those patients who do not respond to the immunotherapies now available.
Immunotherapy is thought to enhance the antitumor responses of cytotoxic T lymphocytes (CTLs); i.e., CD8 + T cells that infiltrate into the tumor 5 . Indeed, a high density of tumor-infiltrating lymphocytes (TILs) is predictive of a good prognosis in a wide range of cancers 6, 7 . However, it remains unclear why the degree of infiltration by TILs varies substantially even between people with the same cancer. It is also unknown whether there are merely quantitative differences in TILs or whether qualitative differences also exist in TILs from tumors with a high TIL density that might contribute to the superior outcome seen in patients with such tumors. Understanding of the TIL transcriptome and the molecular basis of TIL heterogeneity could not only lead to novel biomarkers for patient stratification for therapy but also identify novel immunological pathways to be targeted by future immunotherapeutic strategies.
So far, transcriptional studies of CD8 + T cells from patients with cancer have analyzed cells in peripheral blood or metastatic sites [8] [9] [10] [11] . The precise state of the activation, differentiation and function of CD8 + T cells within primary tumors is poorly understood; however, this must be a key reference point from which to begin elucidating the biology of immunological attack at the time of diagnosis, during tumor progression and after intervention with immunotherapy. To fully characterize the molecular nature of immune responses at the tumor site, we have taken an unbiased approach to define the global transcriptional profile of purified CD8 + TILs from wellcharacterized cohorts of patients with two epithelial cancers: nonsmall-cell lung cancer (NSCLC), and head-and-neck squamous-cell cancer (HNSCC).
RESULTS

Major transcriptional changes characterize CD8 + TILs
To identify the core transcriptional signature of CD8 + TILs, we used RNA-based next-generation sequencing (RNA-Seq) to analyze purified populations of CD8 + T cells present in tumor samples (CD8 + TILs) from patients (n = 36) with treatment-naive early-stage NSCLC ( Supplementary Fig. 1a and Supplementary Tables 1 and 2 ). We also generated matched transcriptional profiles of CD8 + T cells isolated from the adjacent non-tumor lung tissue (CD8 + N-TILs) to discriminate features linked to lung-tissue residence from those related to tumor infiltration. To assess conservation of the transcriptional program of CD8 + TILs in a related solid tumor of epithelial origin, we used a similar data set generated from patients (n = 41) with HNSCC from both human papilloma virus-positive (virus-driven) subtypes and human papilloma virus-negative subtypes.
We identified a large number of transcripts (n = 1,403) that were expressed differentially by CD8 + TILs relative to their expression by CD8 + N-TILs ( Fig. 1a and Supplementary Table 3) , which suggested major changes in the transcriptional landscape of CD8 + TILs in lung tumor tissue. The expression of such lung-cancer 'CD8 + TIL-associated transcripts' did not differ according to histological subtype ( Supplementary Fig. 1b) . Principal-component analysis and hierarchical clustering also showed that CD8 + TILs from both subtypes of lung cancer mostly clustered together, distinct from the CD8 + N-TILs ( Fig. 1b and Supplementary Fig. 1c,d) . Notably, that set of lung-cancer 'CD8 + TIL-associated transcripts' was expressed similarly by CD8 + TILs in both subtypes of HNSCC ( Fig. 1a and Supplementary Fig. 1b) , which also clustered together with CD8 + TILs from lung cancer ( Fig. 1b and Supplementary Fig. 1c,d) ; this indicated a conserved TIL transcriptome for these two tumor types.
Features associated with inhibited function, anergy and senescence of T cells have been described for TILs [12] [13] [14] . Gene-set-enrichment analysis (GSEA) revealed significantly higher expression of genes encoding molecules linked to the so-called 'exhaustion stage' , such as PDCD1 (which encodes the immunological-checkpoint molecule PD-1), CTLA4 (which encodes the immunomodulatory receptor CTLA-4 (CD152)) and HAVCR2 (which encodes the cell-surface marker TIM-3) in CD8 + TILs than in CD8 + N-TILs, while CD8 + TILs did not have higher expression of genes encoding molecules associated with T cell anergy and senescence (Fig. 1c,d ). Our data set also showed higher expression of T cell-associated genes derived from The Cancer Genome Atlas (TCGA) of lung cancer 15 in CD8 + TILs than in CD8 + N-TILs (Fig. 1d) . Together these findings suggested that our strategy for 'micro-scaled' RNA-Seq analysis of freshly purified ex vivo CD8 + TILs and CD8 + N-TILs reliably identified transcripts previously linked to TILs. N-TILs from donors with NSCLC, presented as the running enrichment score (RES) for the gene set as the analysis 'walks down' the ranked list of genes (reflective of the degree to which the gene set is over-represented at the top or bottom of the ranked list of genes) (top), the position of the gene-set members (blue vertical lines) in the ranked list of genes (middle), and the value of the ranking metric (bottom). P values, KolmogorovSmirnov test. Data are from one experiment with n = 32 donors (lung N-TILs), n = 36 donors (NSCLC TILs) and n = 41 donors (HNSCC TILs).
A r t i c l e s
Cell-cycle and TCR-activation pathways in CD8 + TILs To gain broad insight into the functional relevance of the CD8 + TIL transcriptional program, we performed gene-pathway analysis. Notably, we observed significant enrichment in TILs for transcripts from overlapping sets of genes encoding products involved in cell-cycle control, mitosis, DNA replication and signaling via the pathways of the tumor suppressor p53, the cyclin-dependent kinase ATM and the kinase PLK, relative to the abundance of those transcripts in N-TILs (Fig. 2a-c 16, 17 (Fig. 2a,d) . The higher expression of 4-1BB in CD8 + TILs than in N-TILs was confirmed at the protein level by flow cytometry (Fig. 2e) . Together these data suggested that the engagement TCRs and their co-stimulation, presumably provided by antigen-presenting cells expressing tumorassociated antigens (TAAs), were probably involved in the antigenspecific activation and proliferation of CD8 + TILs, which indicated that the tumor milieu sustained the clonal expansion of presumed TAA-specific CD8 + T cells. That suggestion was further supported by analysis of the TCR repertoire, which indicated significantly greater clonal expansion of CD8 + TILs than of N-TILs ( Fig. 2f and Supplementary Table 5 ).
Heterogeneity in targets of immunotherapy
The considerable success of immunological-checkpoint blockers, such as agents directed against PD-1 and CTLA-4, in humans and in model organisms 4, 18 suggests that CD8 + TILs with features of TCR engagement and strong co-stimulation probably mount robust anti-tumor immune responses. However, the response to such treatment is highly variable and is limited to a minority of patients. We reasoned that the molecular profile of CD8 + TILs might explain the inter-person variability in the response to agents directed against PD1 or CTLA-4 and might also reveal alternative immune-system-evasion mechanisms beyond PD-1-and CTLA-4-based pathways. Therefore, we assessed the expression of a spectrum of potential targets of immunotherapy to determine the extent of molecular heterogeneity in CD8 + TILs. We observed substantial variability in the expression of transcripts encoding PD-1 and other potential targets of immunotherapy by CD8 + TILs from patients with lung cancer (Fig. 3a,b) or HNSCC ( Supplementary Fig. 2 ). We confirmed PD-1 expression at the protein level and showed that the abundance of PDCD1 transcripts correlated with the average number of PD-1-expressing cells in the tumors (Supplementary Fig. 3a,b) . We also found varying combinations of expression of co-inhibitory molecules; for example, CD8 + TILs from some patients with lung cancer had upregulation of transcripts encoding four targets of immunotherapy (PD-1, TIM-3, LAG-3 and CTLA-4) relative to the expression of those transcripts by other patients, while some patients showed upregulation of expression of three or two molecules or even a single molecule (Fig. 3a,b) . The high molecular resolution and breadth of our data suggested that baseline transcriptional profiling of tumor-infiltrating CD8 + T cells might guide the selection of appropriate immunotherapies for each patient and the development of biomarkers that can be used to predict the clinical response to checkpoint blockade with monotherapy or combination therapies.
PDCD1 expression correlates with TIL density
The considerable heterogeneity observed in the abundance of PDCD1 transcripts led us to investigate factors linked to PDCD1 expression in CD8 + TILs. Despite the perceived role of PD-1 as a negative regulatory immunological checkpoint, it serves as a marker for clonally expanded, antigen-specific T cells capable of lysing autologous tumor cells 19, 20 . Furthermore, we found a strong positive correlation between the expression of PDCD1 and that of 4-1BB (Fig. 3c) , which is expressed following engagement of the TCR and is thus a marker of antigen-specific T cells 16, 17, 21 . The heterogeneity in the expression of these surrogate markers for antigen specificity suggested that not all tumors contained similar numbers of tumor-reactive CD8 + TILs. Hence, we sought to determine which factors might influence the enrichment for PDCD1-or 4-1BB-expressing CD8 + TILs; i.e., cells we presumed to be TAA specific. We found no correlation between the abundance of PDCD1 or 4-1BB transcripts and clinical or pathological characteristics such as patient age, sex, histological subtype, stage of disease, performance status (the ability to perform activities of daily living without assistance) or smoking status (Supplementary Fig. 3c ).
However, there was a positive correlation between the abundance of each of those transcripts and the average number of CD8 + TILs that infiltrated each tumor sample (Fig. 3c) . A similar correlation was also observed between the abundance of each of those transcripts and CD8A transcripts (encoding the co-receptor CD8α) in lung-tumor samples from the TCGA RNA-Seq data set ( Fig. 3d) . In addition to their higher expression of PDCD1 and 4-1BB, tumors with a high density of TILs ('TIL hi ' tumors; tumors were classified as TIL hi , TIL int and TIL lo on the basis of the average number of CD8 + T cells that infiltrated the tumors; Supplementary Fig. 4 ) also had higher expression of transcripts encoding several other targets of immunotherapy, such as TIM-3, LAG-3 or TIGIT, than that of TIL lo tumors (Fig. 3e) . Published studies have linked PD-1 and 4-1BB to both exhaustion 22 and antigen-specific TCR activation 19, 20 , but the positive correlation of their expression with TIL density indicated that their higher expression probably reflected enrichment for activated TAA-specific CD8 + T cells.
TIL hi tumors show enrichment for CD8 + T RM cells
Patients with a high density of TILs in tumors have a better survival outcome that that of patients with a low density of TILs 6 . It is not known if beyond the numerical changes in T cells, there are qualitative differences between these groups in tumor-infiltrating CD8 + T cells. Defining such features might provide insight into the mechanisms that govern the magnitude and specificity of anti-tumor CD8 + T cell responses.
We found 109 transcripts whose expression differed significantly between TIL hi tumors and TIL lo tumors ( Fig. 4a and Supplementary Table 6 ). As expected, transcripts encoding products involved in TCR activation (4-1BB and PDCD1) were upregulated in TIL hi tumors (Fig. 4a) , consistent with enrichment for presumed TAA-specific CD8 + T cells, although such specificity would require further experimental confirmation. Several other transcripts encoding products associated with the tissue retention of lymphocytes and tissue-resident memory T cells (T RM cells) were expressed differentially by TIL hi tumors relative to their expression by TIL lo tumors (Supplementary Table 6 and Supplementary Fig. 5a ). For example, ITGAE encodes the α E subunit of the integrin α E β 7 (CD103), which binds the adhesion molecule E-cadherin expressed by epithelial cells in barrier tissues 23, 24 . TIL hi tumors had higher expression of the gene encoding this marker of T RM cells (CD103) than did TIL lo tumors (Fig. 4a,b) , and its expression positively correlated with the average number of A r t i c l e s Mitotic roles of polo-like kinase (9) ATM signaling (13) Hereditary breast cancer signaling (14) Role of CHK proteins in cell cycle checkpoint control (6) p53 Signaling (9) p53 signaling (9) Role of BRCA1 in DNA damage response ( A r t i c l e s CD8 + cells within tumors (Fig. 4c) . That finding was also confirmed in the TCGA lung-cancer data set (Fig. 4c) . We confirmed CD103 expression in CD8 + TILs at the protein level by immunohistochemistry and flow cytometry (Fig. 4d,e) . Surface molecules linked to T RM cells 25, 26 , such as CD69 and CD49a (ITGA1), were co-expressed with CD103, and surface molecules linked to effector memory cells (KLRG1) and central memory cells (CCR7 and CD62L) had lower expression on CD103 + CD8 + TILs than on CD103 − CD8 + TILs ( Fig. 4f and Supplementary Fig. 5b ), which suggested that the former population represented T RM cells. We also observed co-expression of PD-1 and 4-1BB in 6% of CD103 + CD8 + TILs and 4% of CD103 + CD8 + TILs, respectively, in a representative patient sample (Fig. 4e) .
Another transcript with higher expression in TIL hi tumors than in TIL lo tumors was CXCR6 (which encodes the chemokine receptor CXCR6) (Fig. 4a,b) ; not only is CXCR6 expression linked to T RM cells 25 but also CXCR6 is important for the localization and function of tissueresiding T cells 27, 28 . S1PR1 transcripts (encoding the G protein-coupled receptor S1P 1 ) and KLF2 transcripts (encoding the transcription factor KLF2), which are known to be downregulated in T RM cells 23 , were also diminished in TIL hi tumors relative to their abundance in A r t i c l e s TIL lo tumors (Fig. 4b) . Downregulation of S1PR1 is necessary for the egress of T cells from the lymph nodes and their subsequent retention in tissues, as T cells with high expression of S1P 1 are retained in the lymph nodes and also easily exit tissues due to the higher concentration of its ligand (S1P) in the lymph nodes and blood. S1PR1 is a target of KLF2; downregulation of KLF2 has been shown to result in lower expression of S1PR1, and the products of both of these genes together have an important role in the establishment and retention of T RM cells in tissues 29 . GSEA also revealed that TIL hi tumors exhibited low expression of genes typically downregulated among a core set of T RM cell signature genes, such as SIPR5, STK38 and FAM65B 23, 25 (Fig. 4g) . Pathway analysis of the genes expressed differentially by TIL hi tumors relative to their expression by TIL lo tumors showed higher expression (by TIL hi tumors than by TIL lo tumors) of genes encoding products involved in the canonical interferon pathway (Supplementary Fig. 5c ).
Interferon-γ (IFN-γ) was also predicted by Ingenuity pathway analysis to be an upstream regulator of the genes expressed differentially by TIL hi tumors relative to their expression by TIL lo tumors (Fig. 4h) Table 8) .
Consistent with that analysis, the expression of several transcripts encoding products linked to cell cycle and proliferation 32 was substantially upregulated in CD8 + TILs from CD103 hi tumors relative to their expression in such cells from CD103 lo tumors (Fig. 5a,b) . We confirmed by flow cytometry that CD103 + CD8 + TILs expressed the cell-proliferation marker Ki67 (Fig. 5c) . The expression of several transcripts encoding products linked to the cytotoxic function of CD8 + T cells (IFNG, GZMA, GZMB, SEMA7A, KLRB1, CCL3, STAT1, RAB27A, IL21R and FKBP1A) 32 was also significantly upregulated in CD8 + TILs from CD103 hi tumors relative to their expression in such cells from CD103 lo tumors (Fig. 5d,e and Supplementary Table 7) . We confirmed at the protein level that CD103 + CD8 + TILs expressed molecules linked to cytotoxicity, such as granzyme B, granzyme A, perforin and CD107a, and produced IFN-γ ( Fig. 5f and Supplementary  Fig. 7a,b) , and demonstrated that CD103 + CD8 + TILs were the main producers, among CD8 + TILs, of both granzyme A and granzyme B (Supplementary Fig. 7c ). However, we found no significant difference between CD103 + CD8 + TILs and CD103 − CD8 + TILs from each patient in a comparison of the proportion of cells expressing granzyme A, granzyme B, IFN-γ and CD107a; however, perforin had lower expression in CD103 + CD8 + TILs (Supplementary Fig. 7d ). To address the question of whether CD8 + TILs from CD103 hi tumors had greater effector potential, we compared the mean fluorescence intensity of those molecules and the frequency of cells expressing them in CD103 hi tumors relative to that in CD103 lo tumors ( Fig. 5f and Supplementary  Fig. 7e) . Notably, we found that CD8 + TILs from CD103 hi tumors had significantly higher expression of granzyme B than that of CD103 lo tumors (Fig. 5f) . These results suggested that tumors rich in T RM cells (CD103 hi tumors) harbored CD8 + T cells that actively proliferated in the tumor milieu and displayed enhanced production of cytotoxic molecules, all hallmarks of robust anti-tumor immunity.
On the basis of the findings reported above, we hypothesized that a high density of CD103 + TILs in tumors (tumors enriched for T RM cells) might also confer a survival advantage beyond that previously found to be associated with the density of CD8 + TILs 6, 7 . In an independent, large cohort of patients (n = 689) with predominantly early-stage lung cancer (83% stage I-IIIA; Supplementary Table 9) monitored from 2007 to 2016, we assessed retrospectively the survival outcome of patients whose tumors were classified on the basis of the density of cells expressing CD8 or CD103 (Supplementary Table 9) . A higher density of CD8 + TILs was associated with a 28% reduction in mortality (P = 0.077 (Cox proportional-hazards model)) and a trend toward improved survival (Fig. 5g) . Notably, patients with lung cancer who had CD103 hi tumors had significantly lower mortality (34% lower risk of mortality; P = 0.045 (Cox proportional-hazards model)) and a better survival outcome than that of patients with CD103 lo tumors (Fig. 5h) . That finding was also observed in the TCGA data set for lung cancer (Supplementary Fig. 7f ). To better understand the dependence on the density of CD103 and CD8 in tumors, we determined the status of the density of cells expressing CD103 (CD103 hi , CD103 int or CD103 lo ) in tumors pre-classified on the basis of the density of cells expressing CD8. As expected, the proportion of CD103 hi tumors was higher among CD8 hi tumors than among CD8 lo tumors; however, there was some discordance, as tumors with CD103 lo or CD103 int status were also observed among CD8 hi tumors (Fig. 5i) . Notably, even in the subgroup of patients with lung cancer who had a high density of CD8 + TILs (CD8 hi tumors), patients who had tumors with a higher density of cells expressing CD103 (CD103 hi tumors) had significantly lower mortality (60% lower risk of mortality; P = 0.043 (Cox proportional-hazards model)) than that of patients with CD103 lo tumors and survived significantly longer than did patients with CD103 lo tumors (Fig. 5i) . Our results suggested that patients with a robust intra-tumoral T RM cell response had better long-term survival outcomes and that this effect was above that conferred by the density of CD8 + TILs.
Molecules linked to tumor immune response
Tumors with CD8 hi and CD103 hi TIL status had higher expression of transcripts encoding molecules shown to be effective targets of immunotherapy, such as PDCD1, TIM3 and LAG3, and CD8 hi status and CD103 hi status were both independently linked to better anti-tumor immunity and survival outcome. Therefore, we reasoned that other molecules encoded by the list of genes upregulated in tumors with CD8 hi and CD103 hi TIL status might also have important functions in modulating the magnitude and specificity of antitumor immune responses (Fig. 6a and Supplementary Table 7 ). An example of this was CD39 (encoded by ENTPD1), a cell-surface ectonucleotidase that dephosphorylates ATP to AMP (Fig. 6b,c) . We found that the expression of CD39 protein was much higher in CD103 + CD8 + TILs than in CD103 − CD8 + TILs (Fig. 6d) . High concentrations of ATP in the tumor microenvironment can have toxic effects on cells via signaling through the purinergic receptor P2RX7 (refs. 33,34) . Given that CD8 + TILs from CD103 hi tumors and those from CD103 lo tumors exhibited similar expression of transcripts encoding P2RX7 (Fig. 6c) , we speculated that the greater abundance of CD39 probably 'preferentially' protected T RM cells (CD103 + CD8 + TILs) from ATP-induced cell death. Notably, however, adenosine A r t i c l e s produced by CD39 might also suppress the function of natural killer T cells, natural killer cells and probably CD8 + T cells 35, 36 . CD38 is another ectonucleotidase and type II trans-membrane glycoprotein with various functions, including regulation of adenosine signaling, adhesion and transduction of activation and proliferation signals 37, 38 . Expression of CD38 protein was also higher in CD103 + CD8 + TILs than in CD103 − CD8 + TILs (Fig. 6d) . Given that purinergic receptors can be targeted therapeutically, it might be pertinent to determine how CD39 and CD38 modulate ATP and purinergic signaling pathways to influence the development and function of anti-tumor T RM cells (CD103 + CD8 + TILs). CD8 + TILs from CD103 hi tumors had higher expression of several transcripts encoding components of the Notch signaling pathway (NOTCH, RBPJ, DTX2, UBC and UBB), relative to their expression in CD8 + TILs from CD103 lo tumors (Fig. 6b,c) , suggestive of an important role for this pathway in boosting T RM cell responses in lung cancer; this speculation is supported by a report showing that the Notch pathway supports the development of T RM cells in the lungs 39 . CD8 + TILs from CD103 hi tumors had higher expression of transcripts encoding two transcription factors (BATF and NAB1) potentially linked to CD4 + T cell-mediated help of CD8 + T cells, relative to their expression in CD8 + TILs from CD103 lo tumors (Fig. 6b,c) .
Other examples of transcripts upregulated in CD8 + TILs from CD103 hi tumors included KIR2DL4, which encodes the killer-cell immunoglobulin-like receptor KIR2DL4 with activating and inhibitory functions 40 ; expression of KIR2DL4 protein was confirmed in CD103 + CD8 + TILs (Fig. 6d) . HLA-G, a non-classical major histocompatibility complex class I molecule, has been shown to engage KIR2DL4 and increase the production of cytokines and chemokines by natural killer cells 41 . Although the expression of HLA-G is highly restricted, several reports have shown that its expression is increased in tumor tissue, especially in lung cancer 42 , so we speculated that HLA-G expressed in tumors might also convey activation signals via the receptor KIR2DL4 to CTLs. SIRPG encodes SIRPG, a member of the immunoglobulin superfamily of signal-regulatory proteins that interact with the ubiquitously expressed signal-regulatory protein CD47 (ref. 43) . Notably, SIRPG is the only member of that family that is expressed on T cells, and its interaction with CD47 expressed on antigen-presenting cells has been shown to enhance T cell proliferation and IFN-γ production 44 . Given the higher expression of SIRPG transcripts in CD8 + TILs from CD103 hi tumors than in those from CD103 lo tumors (Fig. 6b,c) , we speculated that SIRPG might also serve as an important co-stimulatory molecule and that its function could be exploited to enhance the anti-tumor function of CTLs. Several candidate molecules described here have not been fully assessed for their potential as immunotherapeutic targets in cancer; the importance of these molecules in boosting anti-tumor immune responses should be verified in further functional studies.
DISCUSSION
We have taken an unbiased discovery-based approach to identify transcripts for which CD8 + TILs showed enrichment and those that were linked to robust anti-tumor immune responses and good outcomes. Published transcriptional studies of anti-tumor CD8 + T cells from patients with cancer have been largely restricted to the analysis of whole tumor tissue or of CD8 + T cells from peripheral blood or metastatic sites [8] [9] [10] [11] . Our study surveyed over 100 transcriptomes from purified CD8 + TILs and N-TILs derived from tumor tissue and the best control tissue available: the adjacent uninvolved lung. Bioinformatics analysis of those data sets revealed a core CD8 + TIL transcriptional profile comprising ~1,400 genes that was shared by various tumor subtypes and was distinct from that of N-TILs. This profile suggested extensive molecular reprogramming within the tumor microenvironment and enrichment for presumably TAA-specific cells that were actively proliferating following TCR engagement and co-stimulation, all hallmarks of effective anti-tumor immunity. Despite our use of purified CD8 + TIL populations for our analyses, we observed substantial heterogeneity among patients in their expression of genes encoding molecules involved in the cell cycle, TCR activation, co-stimulation and inhibition. Such underlying molecular heterogeneity in the anti-tumor CTL response might partly explain the variability in clinical responses to the immunological-checkpoint blockers currently available. We propose that baseline transcriptional profiling of purified tumor-infiltrating CTLs might enable the rational selection of immunotherapies. Our strategy of purifying relevant immune-cell populations from relatively small tumor samples and performing 'micro-scaled' RNA-Seq assays to generate high-resolution genome-wide data can be readily applied to any accessible tumor type. This approach can thus be used to develop biomarkers of the response to immunotherapy and to discover novel targets for immunotherapy.
Another unique aspect of our study was our evaluation of CD8 + TIL transcriptomes relative to TIL density (a feature linked to outcome). This analysis revealed various features linked to robust antitumor immune responses, such as TIL density; the most striking of these was tissue residence. CD8 + TILs with enrichment for T RM cells (CD103 hi ) had features of enhanced cytotoxicity and proliferation, which suggested that patients whose tumors had a high density of T RM cell markers, such as CD103, had a more-robust anti-tumor immune response and that this feature in the tumor might independently influence clinical outcome. In a large, independent cohort of patients with lung cancer, we showed that a higher density of cells expressing CD103 was predictive of a better survival outcome. Most notably, we confirmed that this effect was independent of that conferred by the density of CD8 + TILs; this finding was biologically relevant and has not been addressed by published studies, to our knowledge [45] [46] [47] . Thus, our study has not only revealed a close link among TIL density, T RM cell features and enhanced survival but has also shed light on the global molecular features that endow CD8 + TILs from T RM cell-rich tumors with robust anti-tumor properties. We speculate that the generation of a robust anti-tumor T RM cell response should be an important goal of vaccination approaches targeting neo antigens or shared tumor antigens.
Since patients with lung cancer who had a high density of CD8 + or CD103 + TILs had a better survival outcome, our comparison of the transcriptional profiles of CD8 + TILs from tumors with either a high density or a low density of cells expressing CD8 or CD103 would probably highlight features linked to the generation of robust anti-tumor immunity. The list of transcripts expressed differentially included those encoding molecules such as PD-1, TIM-3, CTLA-4, LAG-3, CD27, CD8 and OX40, which are effective targets of cancer immunotherapy in humans or in model organisms. Other molecules in that list might also have an important role in modulating the magnitude and specificity of anti-tumor immune response. For example, several promising molecules that we identified, such as CD38, CD39, BATF, NAB1, KIR2DL4, SIPRG and components of Notch signaling, deserve further investigation as immunotherapeutic targets in cancer. BATF has been shown to regulate the metabolism and survival of CD8 + T cells and to diminish the inhibited phenotype of CD8 + T cells 48, 49 . In a model of infection with lymphocytic choriomeningitis virus, the expression of BATF in CD8 + T cells, induced by the cytokine IL-21 derived from CD4 + T cells, was shown to be essential for maintaining the effector response of CTLs, and overexpression of BATF restored the effector function of CD8 + T cells that had not received help from CD4 + T cells 49 . NAB1 is a transcription factor whose mouse homolog (NAB2) is induced in CD8 + T cells that have received help from CD4 + T cells and is needed to prevent activation-induced cell death of those 'helped' CD8 + T cells 50 . Thus, we hypothesize that NAB1, which has high sequence homology to NAB2, might also have a similar role in preventing the apoptosis of tumor-infiltrating CTLs and that its increased expression might identify tumors in which CD8 + TILs have received help from CD4 + T cells. Further functional experiments will be needed to verify the role of these molecules.
Our study has revealed the transcriptional program of CD8 + TILs at the tumor site and has identified the inter-patient heterogeneity that presumably underlies the variability in clinical responses to checkpoint blockade. It has provided insight into the molecular mechanisms that govern robust anti-tumor CTL responses and lends support to the proposal that anti-tumor vaccines should be designed to enable the generation of CD8 + T RM cells for durable immunity. The ability to perform 'micro-scaled' RNA-Seq analysis of purified CD8 + TILs from patients' tumors allowed us to identify gene-expression programs that might inform personalized immunotherapeutic treatment strategies and thereby provide a useful tool for translational application.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
